We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · July 28, 2021

Effects of Tezepelumab in Patients With Moderate to Severe Uncontrolled Asthma

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Effect of Tezepelumab on Airway Inflammatory Cells, Remodelling, and Hyperresponsiveness in Patients With Moderate-to-Severe Uncontrolled Asthma (CASCADE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
Lancet Respir Med 2021 Jul 09;[EPub Ahead of Print], S Diver, L Khalfaoui, C Emson, SE Wenzel, A Menzies-Gow, ME Wechsler, J Johnston, N Molfino, JR Parnes, A Megally, G Colice, CE Brightling

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading